Enanta Pharmaceuticals
ENTA
159 hedge funds and large institutions have $1.02B invested in Enanta Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 64 increasing their positions, 48 reducing their positions, and 16 closing their positions.
831% more call options, than puts
Call options by funds: $11.7M | Put options by funds: $1.26M
33% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 48
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
19% more capital invested
Capital invested by funds: $856M → $1.02B (+$166M)
3% more funds holding
Funds holding: 154 → 159 (+5)
2.61% less ownership
Funds ownership: 97.69% → 95.08% (-2.6%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$6.05M |
| 2 |
BlackRock
New York
|
+$6.02M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.06M |
| 5 |
Barclays
London,
United Kingdom
|
+$2.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$18.8M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$8.38M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
-$7.01M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$6.67M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$4.39M |
ENTA Hedge Fund Activity: Q3 2022 in Review
159 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2022, worth a combined $1.02B — up 19% from $856M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ENTA positions and 16 closed out — a net gain of 5 holders — while 64 added to existing stakes and 48 trimmed.
The largest buyer was Commodore Capital, opening a new position worth an estimated $6.05M. The largest seller was State Street, cutting an estimated $18.8M.
- 159 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2022, up from 154 in Q2 2022.
- Funds reported $1.02B of Enanta Pharmaceuticals stock for Q3 2022, up 19% quarter-over-quarter.
- 21 funds opened new Enanta Pharmaceuticals positions in Q3 2022 and 16 closed out, a net change of +5 holders.
- The largest Enanta Pharmaceuticals buyer in Q3 2022 was Commodore Capital, an estimated $6.05M added.
- The largest Enanta Pharmaceuticals seller in Q3 2022 was State Street, an estimated $18.8M sold.
Based on aggregated 13F filings for Q3 2022.